| Date | Title | Description |
| 06.01.2026 | Moray Wright features in Professional Adviser | For more than three decades, the Enterprise Investment Scheme has played a significant role in backing founders across the UK. With its expansion at the Budget, it is now positioned to support a far greater number of businesses to scale, no... |
| 03.05.2025 | What is a Knowledge Intensive company? | Knowledge intensive companies are important because they fuel innovation, help develop new technologies and tend to lead to economic growth. Many of these companies have a unique approach to creating value, primarily through intellectual ex... |
| 30.12.2024 | Growth Investor of the Year 2024 Winner | We are delighted to announce that Parkwalk was announced Growth Investor of the Year at the 2024 Growth Investor Awards! It was a fantastic event celebrating the incredible achievements of companies and individuals driving innovation and gr... |
| 07.05.2024 | Parkwalk – EIS explained: what is the Enterprise Investment Scheme?
Conclusion | The Enterprise Investment Scheme (EIS) is a useful tax planning tool for investors to take advantage of 5 generous tax benefits*, as well as investing in some of the brightest minds and world-changing innovations in the UK. Our CEO, Moray W... |
| 07.11.2019 | PredictImmune and Crohn’s & Colitis Foundation announce start of jointly-sponsored study to validate PredictSURE IBD™ in the US market | PredictImmune and Crohn’s & Colitis Foundation announce start of jointly-sponsored study to validate PredictSURE IBD™ in the US market
07-11-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and... |
| 29.10.2019 | PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE IBD™ | PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE IBD™
29-10-2019
An exclusive deal with the French diagnostic specialist Theradiag facilitates the first launch of PredictIm... |
| 29.10.2019 | PredictImmune announces a strategic agreement with Theradiag for French speaking Europe to commercialise PredictSURE IBD™ | An exclusive deal with the French diagnostic specialist Theradiag facilitates the first launch of PredictImmune’s prognostic tests in mainland Europe; and enables inflammatory bowel disease (IBD) patients in France, Belgium, Luxembourg and ... |
| 22.10.2019 | PredictImmune announces new strategic partnership to commercialise its PredictSURE IBD™ prognostic test across North America | PredictImmune announces new strategic partnership to commercialise its PredictSURE IBD™ prognostic test across North America
22-10-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving pat... |
| 22.10.2019 | PredictImmune announces new strategic partnership | PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into an exclusive commercial partnership with KSL Biomedi... |
| 19.09.2019 | PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise to allow future expansion of original IP licence to expand its commercial product pipeline | PredictImmune announces new ‘framework agreement’ with Cambridge Enterprise to allow future expansion of original IP licence to expand its commercial product pipeline
19-09-2019
PredictImmune, developers of pioneering prognostic tools for g... |
| 20.08.2019 | PredictImmune appoints Tim Rea of BGF as non-executive director | PredictImmune appoints Tim Rea of BGF as non-executive director
20-08-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is delighted to we... |
| 31.07.2019 | CIC participates in PredictImmune’s £10 million Series B funding round | CIC participates in PredictImmune’s £10 million Series B funding round
31-07-2019
Cambridge Innovation Capital plc (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosyst... |
| 31.07.2019 | Cambridge-based medtech startup PredictImmune raises £10 million in Series B round to treat immune-mediated diseases | PredictImmune, developers of prognostic tests for guiding treatment in immune-mediated diseases, closed its Series B round of funding at £10 million. The investment, led by Parkwalk and BFG, will enable global commercial expansion and enric... |
| 31.07.2019 | CIC participates in PredictImmune’s £10 million Series B funding round | Funding will accelerate global commercial expansion of the company and support expanding product pipeline of prognostic tools
Cambridge Innovation Capital plc (CIC), the venture capital investor enabling visionaries to build global, categor... |
| 30.07.2019 | Daily funding roundup - July 30th, 2019 | DataGrail raised $5M; Connected2Fiber landed $5.3M; Socio secured $6M; Physna closed $6.9M
DataGrail: DataGrail is a purpose-built privacy management platform that ensures sustained compliance with the GDPR, CCPA, and more. DataGrail has ra... |
| 30.07.2019 | PredictImmune closes Series B funding round, raising £10M | PredictImmune closes Series B funding round, raising £10M
30-07-2019
PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the comp... |
| 30.07.2019 | PredictImmune Closes £10M Series B Funding | PredictImmune, a Cambridge, UK-based developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, completed a £10M Series B funding.
Backers included Parkwalk and Cambridge Enterpri... |
| 30.07.2019 | Cambridge-based PredictImmune raises €11 million Series B to expand its pipeline of prognostic tests for chronic disorders | Cambridge-based PredictImmune is developing prognostic tests to guide treatment options and improving patient outcomes for immune-mediated diseases such as inflammatory bowel disease (IBD), Crohn’s disease, and lupus.
Founded in 2017 as a s... |
| 30.07.2019 | PredictImmune secures £10m funding | PredictImmune, a fast-growth developer of pioneering prognostic tools for immune-mediated diseases, has secured a £10m funding package to accelerate global commercial expansion and support its expanding product pipeline. BGF will provide £4... |
| 30.07.2019 | PredictImmune closes Series B funding round, raising £10M | PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced the completion of its Series B funding, having raised £10M to further acceler... |
| 27.02.2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards
27-02-2019
Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| 13.12.2018 | PredictImmune awarded £100,000 Innovate UK grant | PredictImmune awarded £100,000 Innovate UK grant
13-12-2018
PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced that it has been awarded a grant of £100,000 by Innovate UK, th... |
| 30.04.2018 | PredictImmune Secures £4.3M from Wellcome Trust | PredictImmune, a Cambridge, England, UK-based developer of prognostic tools to guide treatment of patients with immune-mediated diseases, has been awarded £4.3m by the Wellcome Trust.
The funding will be used to support a prospective multi-... |
| 30.04.2018 | PredictImmune secures £4.3m investment from Wellcome Trust | PredictImmune secures £4.3m investment from Wellcome Trust
30-04-2018
PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcom... |
| 30.04.2018 | PredictImmune secures £4.3m investment from Wellcome Trust | PredictImmune, a developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded £4.3m by the Wellcome Trust. The funding will be used to support a prospective multi-centr... |
| - | PredictImmune – Parkwalk co-leads investment alongside BGF | PredictImmune closes Series B funding round, raising £10M to further accelerate global commercial expansion and support expanding product pipeline. |
| - | EIS: more than financial returns | As institutional investors increasingly regard ESG as an important element of their investment decision, Tom Hopkins, of Parkwalk, wonders whether this element of EIS investment should form part of the client conversation. |
| - | Parkwalk – continues impressive investment rate | Parkwalk has invested over £60 million into university spin-outs so far in 2019. |
